{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-065178","form_type":"8-K","ticker":"SABS","cik":"0001833214","company_name":"SAB Biotherapeutics, Inc.","filed_at":"2023-11-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.869811+00:00","generated_at":"2026-06-07T23:30:00.046764+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"SAB Biotherapeutics appoints Katie Ellias to Board of Directors, effective Nov 20, 2023","bullets":["Appointed Katie Ellias as Class II director, effective Nov 20, 2023, until 2026 annual meeting.","Ellias is Managing Director at JDRF T1D Fund (~$200M assets), which invested in SAB.","Board now has 10 directors, 8 independent.","Ellias brings T1D expertise; formerly at Endeavour Vision, Sofinnova Partners, Medtronic, McKinsey."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-065178","json":"https://secwatch.observer/filing/0000950170-23-065178.json","markdown":"https://secwatch.observer/filing/0000950170-23-065178.md","text":"https://secwatch.observer/filing/0000950170-23-065178.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833214/000095017023065178/0000950170-23-065178-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833214/000095017023065178/sabs-20231114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T23:30:00.046764+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ec62e4b513","claim":"Helen Katherine Ellias was appointed as Class II Director at SAB Biotherapeutics, Inc..","evidence_excerpt":"recommended the appointment of, and the Board subsequently appointed, Ms. Helen Katherine Ellias to serve as a Class II director of the Company, effective as of November 20, 2023 until the Company’s 2026 annual meeting of stockholders","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017023065178/0000950170-23-065178-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}